Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study-Reference-Cited by-同舟云学术

Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study

Published:2017-02 Issue:2 Volume:12 Page:390-396
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ito Kentaro,Hataji Osamu,Kobayashi Hiroyasu,Fujiwara Atsushi,Yoshida Masamichi,D’Alessandro-Gabazza Corina N,Itani Hidetoshi,Tanigawa Motoaki,Ikeda Takuya,Fujiwara Kentaro,Fujimoto Hajime,Kobayashi Tetsu,Gabazza Esteban C.,Taguchi Osamu,Yamamoto Nobuyuki

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference15 articles.

1. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

2. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study;Camidge;Lancet Oncol,2012

3. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer;Kwak;N Engl J Med,2010

4. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer;Shaw;N Engl J Med,2013

5. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases;Costa;J Clin Oncol,2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study;Cancer Communications;2024-02-29

2. Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib;Thoracic Research and Practice;2023-07-21

3. Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia;PharmacoEconomics;2023-06-25

4. Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration – a Swedish nationwide retrospective study;Acta Oncologica;2022-11-02

5. Les patients ALK et ROS1 : quelle séquence ?;Revue des Maladies Respiratoires Actualités;2022-10